Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 2150451, 5 pages
http://dx.doi.org/10.1155/2016/2150451
Review Article

Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis

1Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria
2Pediatric Nephrology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany
3Department of Nephrology, UZ Leuven, Leuven, Belgium
4Department of Immunology and Microbiology, KU Leuven, Leuven, Belgium
5Department of Pediatric Nephrology, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Received 23 December 2015; Accepted 27 January 2016

Academic Editor: Keiju Hiromura

Copyright © 2016 Andreas Kronbichler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Jefferson and S. J. Shankland, “The pathogenesis of focal segmental glomerulosclerosis,” Advances in Chronic Kidney Disease, vol. 21, no. 5, pp. 408–416, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Herrod, F. B. Stapleton, R. L. Trouy, and S. Roy, “Evaluation of T lymphocyte subpopulations in children with nephrotic syndrome,” Clinical and Experimental Immunology, vol. 52, no. 3, pp. 581–585, 1983. View at Google Scholar · View at Scopus
  3. S.-A. Hulton, V. Shah, M. R. Byrne, G. Morgan, T. M. Barratt, and M. J. Dillon, “Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome,” Pediatric Nephrology, vol. 8, no. 2, pp. 135–139, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Benz, M. Büttner, K. Dittrich, V. Campean, J. Dötsch, and K. Amann, “Characterisation of renal immune cell infiltrates in children with nephrotic syndrome,” Pediatric Nephrology, vol. 25, no. 7, pp. 1291–1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Prasad, A. K. Jaiswal, V. Agarwal et al., “Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in Childhood Nephrotic Syndrome: A longitudinal study,” Cytokine, vol. 72, no. 2, pp. 190–196, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Le Berre, S. Bruneau, J. Naulet et al., “Induction of T regulatory cells attenuates idiopathic nephrotic syndrome,” Journal of the American Society of Nephrology, vol. 20, no. 1, pp. 57–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Wang, Q. Li, L. Wang et al., “The role of Th17/IL-17 in the pathogenesis of primary nephrotic syndrome in children,” Kidney and Blood Pressure Research, vol. 37, no. 4-5, pp. 332–345, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Masutani, M. Taniguchi, H. Nakashima et al., “Up-regulated interleukin-4 production by peripheral T-helper cells in idiopathic membranous nephropathy,” Nephrology Dialysis Transplantation, vol. 19, no. 3, pp. 580–586, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. C.-C. Yu, A. Fornoni, A. Weins et al., “Abatacept in B7-1-positive proteinuric kidney disease,” The New England Journal of Medicine, vol. 369, no. 25, pp. 2416–2423, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Benigni, E. Gagliardini, and G. Remuzzi, “Abatacept in B7-1-positive proteinuric kidney disease,” The New England Journal of Medicine, vol. 370, no. 13, pp. 1261–1263, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. J. M. Thurman, M. Wong, B. Renner et al., “Complement activation in patients with focal segmental glomerulosclerosis,” PLoS ONE, vol. 10, no. 9, Article ID e0136558, 2015. View at Publisher · View at Google Scholar
  12. J. Strehlau, A. D. Schachter, M. Pavlakis, A. Singh, A. Tejani, and T. B. Strom, “Activated intrarenal transcription of CTL-effectors and TGF-β1 in children with focal segmental glomerulosclerosis,” Kidney International, vol. 61, no. 1, pp. 90–95, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. M. F. O. Souto, A. L. Teixeira, R. C. Russo et al., “Immune mediators in idiopathic nephrotic syndrome: evidence for a relation between interleukin 8 and proteinuria,” Pediatric Research, vol. 64, no. 6, pp. 637–642, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Schramek, R. Sarközi, C. Lauterberg et al., “Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells,” Laboratory Investigation, vol. 89, no. 11, pp. 1304–1316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Bakr, M. Shokeir, F. El-Chenawi, F. El-Husseni, A. Abdel-Rahman, and R. El-Ashry, “Tumor necrosis factor-α production from mononuclear cells in nephrotic syndrome,” Pediatric Nephrology, vol. 18, no. 6, pp. 516–520, 2003. View at Google Scholar · View at Scopus
  16. Z. I. Niemir, M. Ondracek, G. Dworacki et al., “In situ upregulation of IL-10 reflects the activity of human glomerulonephritides,” American Journal of Kidney Diseases, vol. 32, no. 1, pp. 80–92, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Stefanovic, E. Golubovic, M. Mitic-Zlatkovic, P. Vlahovic, O. Jovanovic, and R. Bogdanovic, “Interleukin-12 and interferon-gamma production in childhood idiopathic nephrotic syndrome,” Pediatric Nephrology, vol. 12, no. 6, pp. 463–466, 1998. View at Publisher · View at Google Scholar
  18. Z. I. Niemir, H. Stein, G. Dworacki et al., “Podocytes are the major source of IL-1α and IL-1β in human glomerulonephritides,” Kidney International, vol. 52, no. 2, pp. 393–403, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Kalavrizioti, M. Gerolymos, M. Rodi et al., “T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: can they predict outcome?” Cytokine, vol. 76, no. 2, pp. 260–269, 2015. View at Publisher · View at Google Scholar
  20. C. Gluhovschi, G. Gluhovschi, E. Potencz et al., “What is the significance of HLA-DR antigen expression in the extraglomerular mesangium in glomerulonephritis?” Human Immunology, vol. 73, no. 11, pp. 1098–1101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Markovic-Lipkovski, C. A. Muller, T. Risler, A. Bohle, and G. A. Muller, “Mononuclear leukocytes, expression of HLA class II antigens and intercellular adhesion molecule 1 in focal segmental glomerulosclerosis,” Nephron, vol. 59, no. 2, pp. 286–293, 1991. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Li, T. Zhang, W. Diao et al., “Role of myeloid-derived suppressor cells in glucocorticoid-mediated amelioration of FSGS,” Journal of the American Society of Nephrology, vol. 26, no. 9, pp. 2183–2197, 2015. View at Publisher · View at Google Scholar
  23. D. Strassheim, B. Renner, S. Panzer et al., “IgM contributes to glomerular injury in FSGS,” Journal of the American Society of Nephrology, vol. 24, no. 3, pp. 393–406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. E. H. Garin, J. Reiser, G. Cara-Fuentes et al., “Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis,” Pediatric Nephrology, vol. 30, no. 3, pp. 469–477, 2015. View at Publisher · View at Google Scholar
  25. J. Reiser, G. Von Gersdorff, M. Loos et al., “Induction of B7-1 in podocytes is associated with nephrotic syndrome,” Journal of Clinical Investigation, vol. 113, no. 10, pp. 1390–1397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. The ACCESS Trial Group, “Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study,” Arthritis & Rheumatology, vol. 66, no. 11, pp. 3096–3104, 2014. View at Publisher · View at Google Scholar
  27. M. S. Joy, D. S. Gipson, L. Powell et al., “Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group,” American Journal of Kidney Diseases, vol. 55, no. 1, pp. 50–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. B. V. Roberts, I. Susano, D. S. Gipson, H. Trachtman, and M. S. Joy, “Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease,” Journal of Clinical Pharmacology, vol. 53, no. 9, pp. 919–924, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Peyser, N. MacHardy, F. Tarapore et al., “Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group,” BMC Nephrology, vol. 11, no. 1, article 2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Trachtman, S. Vento, E. Herreshoff et al., “Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group,” BMC Nephrology, vol. 16, article 111, 2015. View at Publisher · View at Google Scholar
  31. H. Trachtman, F. C. Fervenza, D. S. Gipson et al., “A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis,” Kidney International, vol. 79, no. 11, pp. 1236–1243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. M. J. Kemper, A. Lehnhardt, A. Zawischa, and J. Oh, “Is rituximab effective in childhood nephrotic syndrome? Yes and no,” Pediatric Nephrology, vol. 29, no. 8, pp. 1305–1311, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Fernandez-Fresnedo, A. Segarra, E. González et al., “Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 8, pp. 1317–1323, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Kronbichler, J. Kerschbaum, G. Fernandez-Fresnedo et al., “Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review,” American Journal of Nephrology, vol. 39, no. 4, pp. 322–330, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Trautmann, M. Bodria, F. Ozaltin et al., “Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort,” Clinical Journal of the American Society of Nephrology, vol. 10, no. 4, pp. 592–600, 2015. View at Publisher · View at Google Scholar
  36. A. Kronbichler, D. R. Jayne, and G. Mayer, “Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis,” European Journal of Clinical Investigation, vol. 45, no. 3, pp. 346–368, 2015. View at Publisher · View at Google Scholar
  37. A. Kronbichler and A. Bruchfeld, “Rituximab in adult minimal change disease and focal segmental glomerulosclerosis,” Nephron—Clinical Practice, vol. 128, pp. 277–282, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Fornoni, J. Sageshima, C. Wei et al., “Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis,” Science Translational Medicine, vol. 3, no. 85, Article ID 85ra46, 2011. View at Publisher · View at Google Scholar · View at Scopus